FDA Investigation Unlikely to Influence Biogen's (BIIB) Aduhelm Uptake - Analyst
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
FDA seeks probe into its talks with Biogen before Alzheimer's drug approval
July 9, 2021 2:37 PM EDTBy Manas Mishra
(Reuters) - The U.S. Food and Drug Administration on Friday called for an independent federal probe into its representatives' interactions with Biogen Inc that led to approval of the company's Alzheimer's disease drug last month.
The drugmaker's shares closed down 3% after the agency's acting commissioner Janet Woodcock asked the Office of the Inspector General at the Department of Health and Human Services to probe if the talks were inconsistent with the regulator's policies.
"We received the letter and are reviewing it for appropriate action," Tesia Williams, a spokesperson of HHS's Office of the... More
Biogen (BIIB) Shares Down 4% As Head of FDA Calls for a Federal Investigation into Approval of Aduhelm
July 9, 2021 1:36 PM EDTBiogen (NASDAQ: BIIB) shares are trading 4% lower following a call by the head of the FDA to investigate the infamous Alzheimers drugs approval process.
In an open letter posted on Twitter on Friday, Dr. Janet Woodstock, Acting Commissioner of the FDA,... More
FDA calls for federal investigation into its controversial Alzheimer's drug approval - STAT
July 9, 2021 12:53 PM EDTFDA calls for federal investigation into its controversial Alzheimers drug approval - STAT
Related Stock:
Biogen (NASDAQ: BIIB)
... More